Cargando…

Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease

INTRODUCTION: Advanced glycation end products (AGEs) are produced and can accumulate during chronic inflammation, as might be present in patients with rheumatoid arthritis (RA). AGEs are involved in the development of cardiovascular disease. The aim of this study is to evaluate whether AGEs are incr...

Descripción completa

Detalles Bibliográficos
Autores principales: de Groot, Lodewijk, Hinkema, Helmy, Westra, Johanna, Smit, Andries J, Kallenberg, Cees GM, Bijl, Marc, Posthumus, Marcel D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334658/
https://www.ncbi.nlm.nih.gov/pubmed/22168993
http://dx.doi.org/10.1186/ar3538
_version_ 1782230662700335104
author de Groot, Lodewijk
Hinkema, Helmy
Westra, Johanna
Smit, Andries J
Kallenberg, Cees GM
Bijl, Marc
Posthumus, Marcel D
author_facet de Groot, Lodewijk
Hinkema, Helmy
Westra, Johanna
Smit, Andries J
Kallenberg, Cees GM
Bijl, Marc
Posthumus, Marcel D
author_sort de Groot, Lodewijk
collection PubMed
description INTRODUCTION: Advanced glycation end products (AGEs) are produced and can accumulate during chronic inflammation, as might be present in patients with rheumatoid arthritis (RA). AGEs are involved in the development of cardiovascular disease. The aim of this study is to evaluate whether AGEs are increased in patients with long-standing RA and whether AGE accumulation is related to disease activity, disease severity and measures of (premature) atherosclerosis, such as endothelial activation, endothelial dysfunction and intima media thickness (IMT). METHODS: In a cross-sectional study, 49 consecutive RA patients with longstanding disease (median disease duration of 12.3 years (range 9.3 to 15.1)), receiving standard of care, were included and compared with 49 age- and sex-matched healthy controls (HC). AGEs were determined by skin autofluorescence. Disease activity was evaluated by the Disease Activity Score of 28 joints (DAS-28) score and joint damage by modified Sharp-v.d. Heijde score. Endothelial activation (soluble vascular cellular adhesion molecule-1) sVCAM-1, von Willebrand factor (vWF), thrombomodulin), endothelial dysfunction (determined by small artery elasticity (SAE)) and IMT were measured and related to AGE accumulation. RESULTS: AGEs were increased in RA patients (median 2.4 arbitrary units (a.u.), range 1.6 to 4.2) compared to HC (2.2, 1.3 to 3.8). RA patients had a DAS-28 score of 2.9 (0.8 to 6.9) and a modified Sharp-v.d. Heijde score of 19 (0 to 103). sVCAM-1 and vWF levels were higher in RA patients. SAE was significantly decreased in RA (3.9 ml/mmHg (1.4 to 12.2) vs. 6.1 in HC (1.7 to 12.9). IMT did not differ between the two groups. Combining both groups' AGEs correlated with vWF, sVCAM-1 and IMT, and was inversely related to SAE. In RA, AGEs had an inverse relation with SAE, but did not relate to disease activity or radiological damage. In multivariate analysis for both groups, smoking, glucose levels, vWF, SAE and male gender were significantly related to the formation of AGEs. CONCLUSIONS: AGEs were increased in RA patients with long-standing disease and without signs of premature atherosclerosis. AGEs were related to endothelial activation and endothelial dysfunction. This supports the hypothesis that in RA AGEs may be an early marker of cardiovascular disease.
format Online
Article
Text
id pubmed-3334658
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-33346582012-04-25 Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease de Groot, Lodewijk Hinkema, Helmy Westra, Johanna Smit, Andries J Kallenberg, Cees GM Bijl, Marc Posthumus, Marcel D Arthritis Res Ther Research Article INTRODUCTION: Advanced glycation end products (AGEs) are produced and can accumulate during chronic inflammation, as might be present in patients with rheumatoid arthritis (RA). AGEs are involved in the development of cardiovascular disease. The aim of this study is to evaluate whether AGEs are increased in patients with long-standing RA and whether AGE accumulation is related to disease activity, disease severity and measures of (premature) atherosclerosis, such as endothelial activation, endothelial dysfunction and intima media thickness (IMT). METHODS: In a cross-sectional study, 49 consecutive RA patients with longstanding disease (median disease duration of 12.3 years (range 9.3 to 15.1)), receiving standard of care, were included and compared with 49 age- and sex-matched healthy controls (HC). AGEs were determined by skin autofluorescence. Disease activity was evaluated by the Disease Activity Score of 28 joints (DAS-28) score and joint damage by modified Sharp-v.d. Heijde score. Endothelial activation (soluble vascular cellular adhesion molecule-1) sVCAM-1, von Willebrand factor (vWF), thrombomodulin), endothelial dysfunction (determined by small artery elasticity (SAE)) and IMT were measured and related to AGE accumulation. RESULTS: AGEs were increased in RA patients (median 2.4 arbitrary units (a.u.), range 1.6 to 4.2) compared to HC (2.2, 1.3 to 3.8). RA patients had a DAS-28 score of 2.9 (0.8 to 6.9) and a modified Sharp-v.d. Heijde score of 19 (0 to 103). sVCAM-1 and vWF levels were higher in RA patients. SAE was significantly decreased in RA (3.9 ml/mmHg (1.4 to 12.2) vs. 6.1 in HC (1.7 to 12.9). IMT did not differ between the two groups. Combining both groups' AGEs correlated with vWF, sVCAM-1 and IMT, and was inversely related to SAE. In RA, AGEs had an inverse relation with SAE, but did not relate to disease activity or radiological damage. In multivariate analysis for both groups, smoking, glucose levels, vWF, SAE and male gender were significantly related to the formation of AGEs. CONCLUSIONS: AGEs were increased in RA patients with long-standing disease and without signs of premature atherosclerosis. AGEs were related to endothelial activation and endothelial dysfunction. This supports the hypothesis that in RA AGEs may be an early marker of cardiovascular disease. BioMed Central 2011 2011-12-14 /pmc/articles/PMC3334658/ /pubmed/22168993 http://dx.doi.org/10.1186/ar3538 Text en Copyright ©2011 de Groot et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
de Groot, Lodewijk
Hinkema, Helmy
Westra, Johanna
Smit, Andries J
Kallenberg, Cees GM
Bijl, Marc
Posthumus, Marcel D
Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease
title Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease
title_full Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease
title_fullStr Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease
title_full_unstemmed Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease
title_short Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease
title_sort advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334658/
https://www.ncbi.nlm.nih.gov/pubmed/22168993
http://dx.doi.org/10.1186/ar3538
work_keys_str_mv AT degrootlodewijk advancedglycationendproductsareincreasedinrheumatoidarthritispatientswithcontrolleddisease
AT hinkemahelmy advancedglycationendproductsareincreasedinrheumatoidarthritispatientswithcontrolleddisease
AT westrajohanna advancedglycationendproductsareincreasedinrheumatoidarthritispatientswithcontrolleddisease
AT smitandriesj advancedglycationendproductsareincreasedinrheumatoidarthritispatientswithcontrolleddisease
AT kallenbergceesgm advancedglycationendproductsareincreasedinrheumatoidarthritispatientswithcontrolleddisease
AT bijlmarc advancedglycationendproductsareincreasedinrheumatoidarthritispatientswithcontrolleddisease
AT posthumusmarceld advancedglycationendproductsareincreasedinrheumatoidarthritispatientswithcontrolleddisease